Novus Clinical Research Services

What Novus Clinical Research Services does

Novus Clinical Research Services Ltd. (Novus CRSL) is a privately held Contract Research Organization headquartered in Paribag, Dhaka, Bangladesh, established in 2017. The company delivers an integrated portfolio of six service lines from a single 10,960-square-foot, three-story facility: clinical research (bioequivalence studies, pharmacokinetic studies, clinical trials, randomized control trials, observational studies), diagnostic services (clinical chemistry, hematology, serology, microscopy, urine analysis, ECG), molecular laboratory services (RT-PCR COVID-19 and other molecular testing in a biosafety level-2 facility), analytical services (GLP-compliant LC-MS/MS method development, validation, and sample analysis), medical services (medical writing, pharmacovigilance, medico-marketing support), and project management. The company maintains a 30-bed clinical facility with an Emergency Care Unit and a database of 150 registered volunteers, and has managed approximately 50 projects cumulatively, predominantly international bioequivalence studies.

Novus CRSL serves primarily generic pharmaceutical manufacturers in Bangladesh, with named enterprise clients including Beximco Pharmaceuticals Ltd., Nuvista Pharmaceuticals Ltd., and Synovia Pharma PLC. Secondary segments include academic researchers, scientists, and individual consumers seeking diagnostic testing. The revenue model is project-based professional services across all six lines, with diagnostic health packages offered at 50% discount and free home collection for the consumer segment. Pricing is not publicly disclosed. The company is one of the earliest DGDA-approved CROs in Bangladesh and operates in compliance with GCP, GLP, and ICH guidelines, with additional DGHS, molecular lab, and EPI vaccination permissions.

The company markets and distributes services through direct enterprise sales to pharmaceutical companies and through direct-to-consumer channels including home sample collection for diagnostic and COVID-19 testing. Geographic focus is South Asia, with the stated capability to manage clinical trials conducted both domestically and internationally. No external funding rounds, acquisitions, leadership changes, or partnerships have been disclosed in the available data, and the ownership structure is not publicly detailed.

Name

Novus Clinical Research Services

Legal name

Novus Clinical Research Services Ltd.

Website

https://novuscro.com.bd

Company type

Private

Founded year

2017

Operating status

Operating

Short description

Novus Clinical Research Services is a DGDA-approved Contract Research Organization in Dhaka, Bangladesh, providing bioequivalence studies, clinical trials, LC-MS/MS analytical services, molecular diagnostics, and project management primarily to generic pharmaceutical manufacturers in South Asia.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Contract research organization
• Clinical research services
• Bioequivalence studies
• Pharmacokinetic analysis
• Analytical laboratory testing

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Research Services: Project-based fees for conducting bioequivalence studies, PK studies, clinical trials, randomized control trials, and observational studies for pharmaceutical companies.
2. Diagnostic Testing Services: Fee-for-service diagnostic testing including clinical chemistry, hematology, serology, microscopy, urine analysis, ECG, and health packages with home collection services.
3. Molecular Laboratory Services: RT-PCR testing for COVID-19 and other molecular tests with home collection services, including rapid antigen tests.
4. Analytical Services: Method development, method validation, and sample analysis using LC-MS/MS technology for pharmaceutical analysis.
5. Medical Writing and Support Services: Medical writing for clinical study protocols and reports, publication support, pharmacovigilance consulting, and medico marketing support.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Novus CRSL is a Bangladesh-based Contract Research Organization offering integrated clinical research and bioequivalence services for generic pharmaceutical manufacturers. Service lines include clinical research (bioequivalence, PK, clinical trials, RCTs, observational studies), diagnostic laboratory testing, RT-PCR-based molecular testing (including COVID-19), LC-MS/MS analytical services under GLP, medical writing and pharmacovigilance consulting, and end-to-end project management.

Product overview

Novus Clinical Research Services (Novus CRSL) operates as a Contract Research Organization (CRO) offering a unified portfolio of clinical research services. The integrated service portfolio consists of six core offerings: Clinical Research (bioequivalence studies, clinical trials), Diagnostic Service (laboratory diagnostics), Molecular Laboratory (RT-PCR and molecular testing), Analytical Service (LC-MS/MS based analysis), Medical Service (medical writing, pharmacovigilance), and Project Management. All services are delivered from a single 10,960 square feet facility in Dhaka, Bangladesh, with shared quality management infrastructure, professional staff, and regulatory compliance framework.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Comprehensive clinical research services including bioequivalence studies, pharmacokinetic (PK) studies, clinical trials, randomized control trials, and observational studies. Conducted at a 30-bed clinical facility with an Emergency Care Unit, supported by a database of 150 registered volunteers and trained physicians, nurses, phlebotomists, and clinical staff. Targeted at pharmaceutical manufacturers, researchers, and scientists.
• Diagnostic Service State-of-the-art diagnostic laboratory offering clinical chemistry analysis, hematology analysis, serology, microscopy, urine analysis, and ECG, plus comprehensive health packages with free home collection. Designed for patients, healthcare providers, and corporate health programs at reasonable prices.
• Molecular Laboratory Molecular diagnostics laboratory equipped with sophisticated instrumentation and a biosafety level-2 facility, providing real-time COVID-19 RT-PCR testing, rapid antigen testing, and other molecular tests with home collection services. Targeted at patients and healthcare organizations.
• Analytical Service GLP-compliant analytical laboratory providing method development, method validation, and sample analysis using LC-MS/MS with solid-phase extraction and water purification. Covers therapeutic categories including anti-ulcerant, anti-diabetic, anti-hypertensive, and impurity analysis. Targeted at pharmaceutical manufacturers.
• Medical Service Medical support services including medical writing for clinical study protocols and reports, publication support, medico marketing support, and pharmacovigilance consulting. Targeted at hospitals, researchers, and pharmaceutical businesses.
• Project Management End-to-end project management for clinical studies, coordinating with sponsors, managing timelines and budgets, and ensuring regulatory and quality compliance across study execution. Targeted at pharmaceutical companies and sponsors of clinical research.

Quantifiable outcome

• 50+ international bioequivalence studies managed
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Semler Research Center: India-based clinical and bioanalytical CRO with bioequivalence and pharmacokinetic study offerings — directly comparable in scope of services, customer base (generic pharma), and BA/BE regulatory positioning.
• Aizant Drug Research Solutions: India-based CRO specializing in bioequivalence and Phase I clinical studies with in-house bioanalytical lab — analogous emerging-market CRO competing for similar generic-sponsor BE work.
• Accutest Research Laboratories (Aragen): India-headquartered bioanalytical CRO (formerly Accutest) with LC-MS/MS capability supporting BE studies — comparable on analytical platform and generic-pharma customer profile.
• Veeda Clinical Research: India-based CRO offering bioequivalence, Phase I, and bioanalytical services to global generic and innovator pharma — directly comparable on service mix and customer type.
• Lambda Therapeutic Research: India-based clinical and bioanalytical CRO with a strong bioequivalence and Phase I focus — directly comparable to Novus on BE study execution and bioanalytical (LC-MS/MS) capability for generics.

Emerging players

• Clinica Smart Solutions (CliniOps / CliniScripts-equivalent South Asian CROs): South Asian emerging clinical CRO with bioequivalence and clinical trial services; a smaller-scale peer with overlapping regional generic-pharma customers.

Broad incumbents

• SGS Health Science: Global clinical and bioanalytical CRO services including BE studies; incumbent alternative sponsors may select instead of an emerging-market CRO like Novus.
• Eurofins Clinical Trial Testing: Global lab services platform with central laboratory and bioanalytical capabilities for clinical trials — overlapping with Novus's central lab/LC-MS/MS offerings but at vastly greater scale.
• IQVIA: Global CRO incumbent serving large innovator and generic sponsors with full Phase I–IV capabilities; represents the upper-end competitor Novus positions against on cost and emerging-market access.
• ICON plc: Global full-service CRO with Phase I–IV and bioanalytical; broad incumbent competitor for international sponsors evaluating South Asian CRO partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novus Clinical Research Services